

## Reduction of $\alpha,\alpha$ -dialkoxy-substituted nitroxides: the synthesis of $\alpha$ -alkoxynitrones and acetals of *N*-hydroxyamides

S. M. Bakunova,\* I. A. Grigor'ev, I. A. Kirilyuk, and L. B. Volodarsky


N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 9 prosp. Akad. Lavrent'eva, 630090 Novosibirsk, Russian Federation.

Fax: +7 (383 2) 34 4752. E-mail: sveta@nioch.nsc.ru

Reduction of stable nitroxides derived from tetrahydrooxazole, tetrahydroimidazole, 2,5-dihydroimidazole, and 2,5-dihydroimidazole 3-oxide containing alkoxy groups in  $\alpha$ -position to the nitroxyl group affords  $\alpha$ -alkoxynitrones, acetals of *N*-hydroxyamides, or their equilibrium mixtures.


**Key words:** nitroxides,  $\alpha$ -alkoxynitrones,  $\alpha$ -methoxynitrones, 2,5-dihydroimidazoles, 2,5-dihydroimidazole 3-oxides, 2*H*-imidazole *N*-oxides, 4*H*-imidazole *N*-oxides, 4,5-dihydrooxazole 3-oxides, ring-chain tautomerism.

Earlier,<sup>1–5</sup> we proposed a method for the synthesis of stable nitroxyl radicals (SNRs) bearing alkoxy groups at the nitroxyl  $\alpha$ -carbon atom by oxidation of nitrones in methanol and other alcohols (oxidative alkoxylation). It was determined that this transformation proceeds via intermediate  $\alpha$ -alkoxynitrones, not easily available compounds, which are interesting because of their high reactivity, especially in reactions of nucleophilic substitution and 1,3-dipolar cycloaddition.<sup>6–8</sup> A possible preparative application of oxaloxynitrones was shown with the synthesis of 4-methoxy-1,2,2,5,5-pentamethyl-2,5-dihydroimidazole 3-oxide (**1**) as an example.<sup>1</sup>




However, in other cases, the reaction cannot be stopped at the stage of formation of  $\alpha$ -alkoxynitrones and results in SNRs or destruction products. For example, the oxidation of *N*-(2-hydroxyethyl)-1,1-dimethyl-2-phenylethyl- $\alpha$ -(3-nitrophenyl)nitrone in aprotic solvents yields a mixture of benzaldehyde, 3-nitrobenzaldehyde, and acetone instead of the expected cyclic  $\alpha$ -alkoxynitrone, 4,4-dimethyl-2-(3-nitrophenyl)-5-phenyl-4,5-dihydrooxazole 3-oxide (**2a**), while the oxidation in methanol affords only 2-methoxy-4,4-dimethyl-2-(3-nitrophenyl)-5-phenyl-2,3,4,5-tetrahydrooxazole-3-oxyl (**3a**).


Compound **2a** was obtained<sup>3</sup> in high yield by reducing SNR **3a**. One could expect that reduction of other SNRs containing alkoxy groups at the nitroxyl  $\alpha$ -carbon atom would also result in  $\alpha$ -alkoxynitrones (AN). However, the reduction of 2,2-dialkoxy-2,5-dihydroimidazole-1-oxyl 3-oxides is not accompanied by elimination of an alcohol molecule, giving stable hydroxylamines (HA), 2,2-dialkoxy-1-hydroxy-2,5-dihydroimidazole 3-oxides.



To clear up just how far these two possible reaction pathways are general, we studied the reduction of various SNR with alkoxy groups at the nitroxyl  $\alpha$ -carbon atom. SNRs **3–10** were used as substrates and hydroxylamine and zinc in the presence of ammonium chloride as reducing agents.




Like the previously described reduction of SNR **3a**,<sup>3</sup> the reduction of SNRs **3b–d** with hydroxylamine in methanol yields the corresponding 4,5-dihydrooxazole 3-oxides **2b–d**, compounds **2b,d** being easily hydrolyzable in air to give *N*-(2-aryloxy-1,1-dimethyl-2-phenylethyl)hydroxylamines (**11b,d**). The reduction of SNRs **3b,d** with zinc in the presence of ammonium chloride immediately results in compounds **11b,d**.



R = 3-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub> (a), Ph (b), 4-Py (c), 4-MeOC<sub>6</sub>H<sub>4</sub> (d)

Scheme 1



R = Ph (a), CONH<sub>2</sub> (b)

The reduction of SNRs **4**, **6a,b**, and **10** is also accompanied by elimination of a methanol molecule and gives the corresponding methoxynitrones **12**, **13a,b**, and **1**, irrespective of the method of reduction (Scheme 1). The highest yields were reached with zinc and ammonium chloride as reducing agents. The reduction of the iminonitroxyl radical **5** also affords 2-methoxy-4,4-dimethyl-5-phenyl-4*H*-imidazole 3-oxide (**12**), which allows mixtures of radicals **4** and **5** (formed in the oxidative methoxylation of 4,4-dimethyl-5-phenyl-4*H*-imidazole 3-oxide<sup>2</sup>) to be used without separation for preparative synthesis of compound **12**. Compound **14** was isolated from the reaction mixture as a by-product. Its yield increases (up to 10–50%) as the reaction temperature increases. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of this compound show signals for a methoxy group at  $\delta$  3.90 and 55.92, respectively; in addition, its <sup>13</sup>C NMR spectrum contains two signals for the carbon atoms of the imino groups at  $\delta$  169.22 and 198.62 typical of 4*H*-imidazole derivatives (see Ref. 2). Based on these data, the structure of 2-methoxy-4,4-dimethyl-5-phenyl-4*H*-imidazole (presumably, a product of more profound reduction) was assigned to compound **14**.


The methoxynitrones **12** and **13a** obtained are liquids that gradually isomerize at room temperature to give compounds **15** and **17**, as in the case of 4-methoxy-2,2,5,5-tetramethyl-2,5-dihydroimidazole 3-oxides.<sup>1</sup> Compound **15** is able to bind a molecule of water. Its covalent hydrate **16** was isolated in the individual state (according to NMR spectroscopic data, it is dehydrated in DMSO to regain form **15**). Methoxynitron **13b** is a stable crystalline compound. The IR spectra of methoxynitrones **12** and **13a,b** reveal bands at 1610–1640 cm<sup>–1</sup>

characteristic of the C=N bond in an  $\alpha$ -methoxynitron group, and their <sup>13</sup>C NMR spectra contain signals at  $\delta$  148–153 for the carbon atoms of this group (cf. Refs. 7, 9, and 10).

Similar to the previously described reduction of 2,2-dimethoxy-2,5-dihydroimidazole-1-oxyl 3-oxide (**8**),<sup>2</sup> the reduction of SNRs **7** and **9** occurs without elimination of a methanol molecule to give dimethyl acetals of cyclic *N*-hydroxylamides **18** and **19** (Scheme 2). Unlike 1-hydroxy-2,2-dimethoxy-5,5-dimethyl-4-phenyl-2,5-dihydroimidazole 3-oxide (**20**),<sup>2</sup> which is a stable crystalline compound, its isomeric 1-hydroxy-5,5-dimethoxy-2,2-dimethyl-4-phenyl-2,5-dihydroimidazole 3-oxide (**19**) gradually isomerizes at room temperature into 1-methoxy-1,2-dihydroimidazol-5-one (**21**), and 1-hydroxy-2,2-dimethoxy-4,4-dimethyl-5-phenyltetrahydrooxazole (**18**) is transformed into *N*-(2-methoxycarbonyloxy-1,1-dimethyl-2-phenylethyl)hydroxylamine (**22**) in quantitative yield upon chromatography on silica gel (similarly to the above-mentioned hydrolysis of 4,5-dihydrooxazole 3-oxides **2**).

NMR and UV spectroscopic data suggest that in methanol there exists an equilibrium mixture of compound **19** with 5-methoxy-2,2-dimethyl-4-phenyl-2*H*-imidazole 1,3-dioxide (**23**). When solutions of compound **19** in

Scheme 2



$\text{CD}_3\text{OD}$  are kept for a long period of time at room temperature, the methoxy groups in compounds **19** and **23** are gradually replaced by  $\text{CD}_3\text{O}$  groups, and methoxynitron **23** partially isomerizes into compound **21**.


The reversible character of addition of a methanol molecule to methoxynitron **23** changes our concept of the mechanism of oxidative alkoxylation of 2,2-dimethyl-4-phenyl-2*H*-imidazole 1,3-dioxide<sup>5</sup>: the formation of SNR **9** in this reaction seems not to follow the cation-radical mechanism, as supposed earlier, but occurs as a result of oxidation of compound **19** formed upon nucleophilic addition of methanol to methoxynitron **23**. In other cases, oxidative alkoxylation of alkoxy-nitrones may also proceed *via* addition of alcohol followed by oxidation.

Apparently, all alkoxy-nitrones can reversibly bind an alcohol molecule, and the point of this equilibrium depends on the character of substituents at the nitron (acetal) carbon atom. Introduction of an *N*-oxide fragment and an acceptor heteroatom into the neighboring position with respect to the acetal carbon atom stabilizes the corresponding acetal.

Unlike 1-hydroxy-2,5-dihydroimidazole 3-oxide (**19**), solutions of compound **20** in  $\text{CD}_3\text{OD}$  contain no admixture of the corresponding methoxynitron even in the presence of  $\text{CD}_3\text{ONa}$  (NMR spectroscopic data). However, the methoxy groups are gradually replaced by  $\text{CD}_3\text{O}$  groups under the action of  $\text{CD}_3\text{ONa}$  in  $\text{CD}_3\text{OD}$ . Such replacement can proceed *via* intermediate methoxynitron **24** (Scheme 3).

One could expect that the reversible character of addition of a methanol molecule to methoxynitrones would also allow introduction of other alkoxy groups


Scheme 3




into the substrate molecule. Oxidation of methoxynitron **13a** with manganese dioxide in ethylene glycol resulted in SNR **25**, which cannot be obtained by oxidizing 2,2-dimethyl-4-phenyl-2*H*-imidazole 1-oxide under the same conditions (Scheme 4).

It is known that dioxolane derivatives are usually more stable than dimethyl acetals. Indeed, the reduction of SNRs **4** and **6** affords methoxynitrones, whereas that of their spirodioxolane analogs **25** and **27** results in 1-hydroxy-2,5-dihydroimidazoles **26** and **28**. The UV spectra (KBr) of these compounds contain absorption bands at 240 nm that correspond to the absorption of a phenylazomethine fragment and no bands in the longer wavelength region that appeared in their UV spectra are recorded in an alcohol. According to NMR spectroscopic data, compound **26** exists in methanol predomi-


Scheme 4




Scheme 5



nantly in the form of 2*H*-imidazole 1-oxide, and the content of 1-hydroxy-2,5-dihydroimidazole is as low as 8%. In contrast, compound **28** exists in solutions predominantly in a cyclic form, the content of 4*H*-imidazole 3-oxide in  $CD_3OD$  and  $CDCl_3$  being *ca.* 20%.



Scheme 6



R = H or D (a), Me (b)

Previously, it was shown that the reactions of 2,2,5,5-tetramethyl-2,5-dihydroimidazole-1-oxyls and their 3-oxides with methylhydrazine yield, along with 1-hydroxy derivatives as reduction products, 1-methoxy derivatives. Stable nitroxyl radicals **8**, **9**, **25**, and **27** react with methylhydrazine in a similar way, and the methyl group substituting for the hydrogen atom prevents elimination of alcohol or opening of the dioxolane ring, thus stabilizing the acetal fragment (Scheme 5). The 1-methoxy-2,5-dihydroimidazoles **29**–**32** obtained are stable crystalline colorless compounds. However, unstable acetals cannot always be stabilized in this way. For example, we failed to obtain the 1-methoxy derivative from SNR **6a** under these conditions, and compounds **13a** and **17** were isolated from the reaction mixture.

As in the case of compound **20** described above, keeping of compound **29** in  $CD_3OD$  in the presence of  $CD_3ONa$  leads to gradual replacement of the methoxy groups in position 2 of the heterocycle by  $CD_3O$  groups (Scheme 6). Under these conditions, compounds **20** and **29** seem to exist in equilibrium with the corresponding 2-imidazoline 3-oxides (**33a,b**).

Thus, the reduction of SNRs with the alkoxy groups at the nitroxyl  $\alpha$ -carbon atom results, depending on the environment of the acetal fragment, in either  $\alpha$ -alkoxy-nitrones or acetals of *N*-hydroxyamides, the latter being capable of reversible elimination of an alcohol mol-

ecule, which provides grounds to expect them to be as reactive as methoxynitrones, *e.g.*, in reactions with nucleophilic agents.

## Experimental

IR spectra were recorded on Specord M-80 and Bruker IFS 66 spectrometers (crystalline samples in pellets with KBr (concentration 0.25%, pellet thickness 1 mm); liquids in  $CCl_4$  (concentration 5%)). UV spectra were obtained with a Specord UV VIS spectrometer in ethanolic solutions and in pellets with KBr (see above).  $^1H$  NMR spectra of compounds **2**, **11**, **18**, **22**, and **34** were recorded on a Bruker WP 200SY spectrometer. The  $^1H$  and  $^{13}C$  NMR spectra of the other compounds were recorded on a Bruker AC 200 spectrometer in 1–5% solutions with a signal from a solvent as a standard.  $^{13}C$  signals were assigned from an analysis of intensities, *J*-modulated spectra, and the published data.<sup>9,12–15</sup> High-resolution mass spectra were recorded on a Finnigan MAT 8200 spectrometer (direct inlet).

**Table 1.** Characteristics of the compounds synthesized

Com- pound	Yield (%)	M.p. /°C	Found ————— (%)			Molecular formula	IR, ν/cm <sup>-1</sup> (KBr)	UV, λ <sub>max</sub> /nm (log ε) (in ethanol)
			C	H	N			
<b>2b</b>	90	Oil	76.5 76.4	6.4 6.4	5.2 5.3	C <sub>17</sub> H <sub>17</sub> NO <sub>2</sub>		233 (4.04); 332 (3.86)
<b>2c</b>	90	168—170	71.8 71.6	6.2 6.0	10.5 10.4	C <sub>16</sub> H <sub>16</sub> N <sub>2</sub> O <sub>2</sub>	1600, 1570 (C=N, C=C)	335 (3.85)
<b>2d</b>	90	Oil	297.13600 <sup>a</sup> 297.13648			C <sub>18</sub> H <sub>19</sub> NO <sub>3</sub>	2840 (C—H, OMe) <sup>b</sup>	255 (4.03); 308 (4.04)
<b>3d</b>	70	Oil	69.4 69.5	6.4 6.7	4.3 4.3	C <sub>9</sub> H <sub>22</sub> NO <sub>4</sub>	2840 (C—H, OMe) <sup>b</sup>	276 (3.40)
<b>10</b>	60	Oil	55.4 55.3	9.4 9.7	12.6 12.9	C <sub>10</sub> H <sub>21</sub> N <sub>2</sub> O <sub>3</sub>	2840 (C—H, OMe) <sup>b</sup>	228 (3.43); 334 (1.48)
<b>11b</b>	95	159—162	71.0 71.6	6.7 6.7	4.9 4.9	C <sub>17</sub> H <sub>19</sub> NO <sub>3</sub>	1720 (C=O)	230 (4.13)
<b>11d</b>	95	122—125	315.14890 <sup>a</sup> 315.14705			C <sub>18</sub> H <sub>21</sub> NO <sub>4</sub>	1750 (C=O); 2830 (C—H, OMe)	258 (4.25)
<b>12</b>	70	Oil	218.10535 <sup>a</sup> 218.10552			C <sub>12</sub> H <sub>14</sub> N <sub>2</sub> O <sub>2</sub>	1620, 1595 (C=N) <sup>b</sup> ; 2840 (C—H, OMe) <sup>b</sup>	225 (3.62); 240 (3.70); 401 (3.43)
<b>13a</b>	70	Oil	218.1046 <sup>a</sup> 218.1055			C <sub>12</sub> H <sub>14</sub> N <sub>2</sub> O <sub>2</sub>	1610, 1515 (C=N) <sup>c</sup> ; 2865 (C—H, OMe) <sup>c</sup>	230 (4.33); 270 (4.34)
<b>13b</b>	90	150—160 (decomp.)	45.7 45.4	6.3 6.0	23.0 22.7	C <sub>7</sub> H <sub>11</sub> N <sub>3</sub> O <sub>3</sub>	1690 (C=O); 1640, 1570 (C=N); 2860 (C—H, OMe); 1710 (C=O) <sup>c</sup> ; 3520, 3470, 3400 (NH) <sup>c</sup>	318 (3.63)
<b>14</b>	50	48—50	70.8 71.3	6.7 6.9	13.7 13.9	C <sub>12</sub> H <sub>14</sub> N <sub>2</sub> O	1630 (C=O); 2830 (C—H, OMe)	257 (3.95); 280 (4.00)
<b>16</b>	50	158—165 (decomp.)	61.1 61.0	6.8 6.8	11.9 11.9	C <sub>12</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub>	1725 (C=O); 2830 (C—H, OMe)	
<b>17</b>	90	Oil	218.10543 <sup>a</sup> 218.1055			C <sub>12</sub> H <sub>14</sub> N <sub>2</sub> O <sub>2</sub>	1720 (C=O) <sup>c</sup> ; 2840 (C—H, OMe) <sup>c</sup>	265 (4.12)
<b>18</b>	90	Oil					2840 (C—H, OMe) <sup>b</sup> ; 3590, 3470 (OH) <sup>b</sup>	
<b>19</b>	70	120—122	58.6 58.6	6.8 6.8	10.4 10.4	C <sub>13</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub>	1575, 1560 (C=N, C=C); 2850 (C—H, OMe)	287 (4.24)
<b>21</b>	90	83—85	61.8 61.5	6.2 6.0	11.9 12.0	C <sub>12</sub> H <sub>14</sub> N <sub>2</sub> O <sub>3</sub>	1725 (C=O); 2830 (C—H, OMe)	232 (4.14); 305 (3.95)
<b>22</b>	70	108—110	60.5 60.3	7.0 7.1	5.8 5.9	C <sub>12</sub> H <sub>17</sub> NO <sub>4</sub>	1760 (C=O); 2850 (C—H, OMe)	252 (2.25); 258 (2.41); 264 (2.30)
<b>25</b>	50	115—117	63.5 63.2	6.4 6.1	11.2 11.3	C <sub>13</sub> H <sub>15</sub> N <sub>2</sub> O <sub>3</sub>	1620 (C=N)	248 (4.23)
<b>26</b>	90	98—101	63.3 62.9	6.7 6.5	11.2 11.3	C <sub>13</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub>	1620 (C=N)	238 <sup>d</sup> ; 228 (4.05); 265 (3.99)
<b>28</b>	70	170—173	62.9 62.9	6.6 6.5	11.4 11.3	C <sub>13</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub>	1600 (C=N)	244 <sup>d</sup> ; 244 (4.10); 401 (2.09)
<b>29</b>	30	90—93	60.4 60.0	7.2 7.2	10.4 10.0	C <sub>14</sub> H <sub>20</sub> N <sub>2</sub> O <sub>4</sub>	2820, 2850 (C—H, OMe)	290 (3.96)
<b>30</b>	25	78—80	60.0 60.0	7.2 7.2	9.6 10.0	C <sub>14</sub> H <sub>20</sub> N <sub>2</sub> O <sub>4</sub>	2815, 2840 (C—H, OMe)	290 (4.23)
<b>31</b>	20	48—50	64.6 64.1	7.0 6.9	10.6 10.7	C <sub>14</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub>	2810 (C—H, OMe) <sup>b</sup>	244 (4.13)
<b>32</b>	25	99—102	64.3 64.1	7.0 6.9	10.6 10.7	C <sub>14</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub>	2800 (C—H, OMe)	244 (4.15)
<b>34</b>	68	152—154	72.5 72.2	7.0 7.0	4.7 4.7	C <sub>18</sub> H <sub>21</sub> NO <sub>3</sub>	2850 (C—H, OMe)	310 (4.44)

<sup>a</sup> m/z. <sup>b</sup> In CCl<sub>4</sub>. <sup>c</sup> In CHCl<sub>3</sub>. <sup>d</sup> In KBr.

Table 2.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectral data for the heterocyclic compounds synthesized

Compound	Solvent	$^1\text{H}$ NMR, $\delta$ , J/Hz	$^{13}\text{C}$ NMR, $\delta$
2b	$\text{CD}_3\text{OD}$	1.06, 1.73 (both s, each 3 H, gem. Me); 5.81 (s, 1 H, CH); 7.49 (m, 5 H, Ph); 7.30, 8.10 (both m, 3 H and 2 H, N=C—Ph)	
2c	$\text{CDCl}_3$	1.05, 1.69 (both s, each 3 H, gem. Me); 5.51 (s, 1 H, CH); 7.49 (m, 5 H, Ph); 8.31, 8.77 (AA'BB', Py, $J = 6$ )	
2d	$\text{CDCl}_3$	1.02, 1.67 (both s, each 3 H, gem. Me); 3.84 (s, 3 H, OMe); 5.43 (s, 1 H, CH); 7.37 (m, 5 H, Ph); 6.96, 8.51 (AA'BB', $\text{C}_6\text{H}_4$ , $J = 9$ )	
12	$\text{CDCl}_3$	1.71 (s, 6 H, gem. Me); 4.28 (s, 3 H, OMe); 7.48, 8.00 (both m, 3 H and 2 H, Ph)	22.75 (gem. Me); 57.92 (OMe); 76.70 ( $\text{CMe}_2$ ); 152.78 (C=NO); 180.07 (C=N); Ph: 129.61 ( $\text{C}_i$ ); 127.15 ( $\text{C}_o$ ); 128.96 ( $\text{C}_m$ ); 132.79 ( $\text{C}_p$ )
13a	$\text{CD}_3\text{OD}$	1.60 (s, 6 H, gem. Me); 4.48 (s, 3 H, OMe); 7.53, 8.11 (both m, 3 H and 2 H, Ph)	24.06 (gem. Me); 59.51 (OMe); 94.89 ( $\text{CMe}_2$ ); 148.18 (C=NO); 161.49 (C=N); Ph: 131.46 ( $\text{C}_i$ ); 128.86 ( $\text{C}_o$ ); 129.63 ( $\text{C}_m$ ); 133.03 ( $\text{C}_p$ )
13b	$\text{CDCl}_3$	1.51 (s, 6 H, gem. Me); 4.32 (s, 3 H, OMe); 6.70, 7.00 (both br.s, each 1 H, $\text{NH}_2$ )	23.51 (gem. Me); 59.27 (OMe); 94.63 ( $\text{CMe}_2$ ); 156.06 (C=NO); 160.93 (C=N); 156.07 (C=O)
14	$(\text{CD}_3)_2\text{SO}$	1.47 (s, 6 H, gem. Me); 3.90 (s, 3 H, OMe); 7.56, 8.09 (both m, 3 H and 2 H, Ph)	20.05 (gem. Me); 55.92 (OMe); 77.30 ( $\text{CMe}_2$ ); 169.22 (O—C=N); 198.62 (C=N); Ph: 129.60 ( $\text{C}_i$ ); 128.79 ( $\text{C}_o$ ); 128.95 ( $\text{C}_m$ ); 132.39 ( $\text{C}_p$ )
15	$(\text{CD}_3)_2\text{SO}$	1.53 (s, 6 H, gem. Me); 3.17 (s, 3 H, OMe); 7.48, 8.00 (both m, 3 H and 2 H, Ph)	22.49 (gem. Me); 49.76 (OMe); 67.05 ( $\text{CMe}_2$ ); 160.45 (C=O); 188.83 (C=N); Ph: 129.64 ( $\text{C}_i$ ); 128.74 ( $\text{C}_o$ ); 129.06 ( $\text{C}_m$ ); 133.17 ( $\text{C}_p$ )
16	$(\text{CD}_3)_2\text{SO}$	0.52, 1.27 (both s, each 3 H, gem. Me); 2.93 (s, 3 H, OMe); 7.61 (m, 5 H, Ph); 8.80 (br.s, 1 H, NH); 9.95 (br.s, 1 H, OH)	17.90, 20.29 (gem. Me); 48.50 (OMe); 67.93 ( $\text{CMe}_2$ ); 91.54 ( $\text{C}=\text{Ph}$ ); 171.70 (C=O); Ph: 136.42 ( $\text{C}_i$ ); 127.06 ( $\text{C}_o$ ); 127.60 ( $\text{C}_m$ ); 128.18 ( $\text{C}_p$ )
	$\text{CD}_3\text{OD}$	0.68, 1.42 (both s, each 3 H, gem. Me); 3.07 (s, 3 H, OMe); 7.46 (m, 5 H, Ph)	18.80, 21.15 (gem. Me); 51.05 (OMe); 71.26 ( $\text{CMe}_2$ ); 93.98 ( $\text{C}=\text{Ph}$ ); 164.43 (C=O); Ph: 137.96 ( $\text{C}_i$ ); 128.91 ( $\text{C}_o$ ); 129.94 ( $\text{C}_m$ ); 130.25 ( $\text{C}_p$ )
17	$\text{CD}_3\text{OD}$	1.47 (s, 6 H, gem. Me); 4.07 (s, 3 H, OMe); 7.34, 8.11 (both m, 3 H and 2 H, Ph)	25.62 (gem. Me); 57.62 (OMe); 94.80 ( $\text{CMe}_2$ ); 159.60 (C=O); 166.70 (C=N); Ph: 131.47 ( $\text{C}_i$ ); 129.32 ( $\text{C}_o$ ); 129.61 ( $\text{C}_m$ ); 132.40 ( $\text{C}_p$ )
18	$(\text{CD}_3)_2\text{CO}$	0.73, 1.27 (both s, each 3 H, gem. Me); 3.35 (s, 3 H, OMe); 3.54 (s, 3 H, OMe); 4.87 (s, 1 H, CH); 7.36 (m, 5 H, Ph)	
19	$\text{CD}_3\text{OD}$	1.63 (s, 6 H, gem. Me); 3.52 (s, 6 H, gem. OMe); 7.51, 8.48 (both m, 3 H and 2 H, Ph)	23.23 (gem. Me); 53.14 (OMe); 91.10 ( $\text{CMe}_2$ ); 112.70 ( $\text{C}(\text{OMe})_2$ ); 138.19 (C=NO); Ph: 127.51 ( $\text{C}_i$ ); 128.85 ( $\text{C}_o$ ); 129.31 ( $\text{C}_m$ ); 132.90 ( $\text{C}_p$ )
21	$\text{CD}_3\text{OD}$	1.76 (s, 6 H, gem. Me); 4.05 (s, 3 H, OMe); 7.52, 8.40 (both m, 3 H and 2 H, Ph)	24.93 (gem. Me); 66.57 (OMe); 89.65 ( $\text{CMe}_2$ ); 163.91 (C=O); 131.10 (C=NO); Ph: 127.00 ( $\text{C}_i$ ); 128.61 ( $\text{C}_o$ ); 129.31 ( $\text{C}_m$ ); 132.21 ( $\text{C}_p$ )
23	$\text{CD}_3\text{OD}$	1.83 (s, 6 H, gem. Me); 3.37 (s, 3 H, OMe); 7.53, 8.28 (both m, 3 H and 2 H, Ph)	23.87 (gem. Me); 61.76 (OMe)
26 <sup>a</sup>	$\text{CD}_3\text{OD}$	1.62 (s, 6 H, gem. Me); 3.85 (t, 2 H, $\text{CH}_2\text{OH}$ , $J = 3$ ); 5.20 (t, 2 H, $\text{CH}_2$ , $J = 3$ ); 7.58, 8.22 (both m, 3 H and 2 H, Ph)	23.96 (gem. Me); 62.05 ( $\text{CH}_2\text{OH}$ ); 74.22 ( $\text{CH}_2$ ); 94.72 ( $\text{CMe}_2$ ); 148.12 (C=NO); 161.96 (C=N); Ph: 131.57 ( $\text{C}_i$ ); 129.08 ( $\text{C}_o$ ); 129.50 ( $\text{C}_m$ ); 133.07 ( $\text{C}_p$ )
26 <sup>b</sup>	$\text{CD}_3\text{OD}$	1.45 (s, 6 H, gem. Me); 4.12, 4.32 (both m, each 2 H, $\text{CH}_2\text{CH}_2$ ); 7.50; 7.85 (both m, 3 H and 2 H, Ph)	25.06 (gem. Me); 64.32, 66.97 ( $\text{CH}_2\text{CH}_2$ )
28 <sup>a</sup>	$\text{CD}_3\text{OD}$	1.75 (s, 6 H, gem. Me); 3.85 (m, 2 H, $\text{CH}_2\text{OH}$ ); 4.80 (m, 2 H, $\text{CH}_2$ ); 7.54, 8.19 (both m, 3 H and 2 H, Ph)	
28 <sup>b</sup>	$\text{CD}_3\text{OD}$	1.50 (s, 6 H, gem. Me); 4.25 (m, 4 H, $\text{CH}_2\text{CH}_2$ ); 7.54, 7.84 (both m, 3 H and 2 H, Ph)	25.06 (gem. Me); 66.90 ( $\text{CH}_2\text{CH}_2$ ); 70.23 ( $\text{CMe}_2$ ); 118.00 (O—C—O); 182.29 (C=N); Ph: 133.68 ( $\text{C}_i$ ); 129.25 ( $\text{C}_o$ ); 129.70 ( $\text{C}_m$ ); 132.65 ( $\text{C}_p$ )
29	$\text{CD}_3\text{OD}$	1.59 (s, 6 H, gem. Me); 3.72 (s, 6 H, gem. OMe); 3.81 (s, 3 H, NOME); 7.55, 8.05 (both m, 3 H and 2 H, Ph)	23.85 (gem. Me); 53.93 (gem. OMe); 64.82 (NOME); 65.90 ( $\text{CMe}_2$ ); 118.70 ( $\text{C}(\text{OMe})_2$ ); 142.80 (C=NO); Ph: 127.51 ( $\text{C}_i$ ); 125.52 ( $\text{C}_o$ ); 129.75 ( $\text{C}_m$ ); 132.11 ( $\text{C}_p$ )

(to be continued)

Table 2 (continued)

Com- pound-	Solvent	<sup>1</sup> H NMR, δ, J/Hz	<sup>13</sup> C NMR, δ
30	CDCl <sub>3</sub>	1.63 (s, 6 H, gem. Me); 3.50 (s, 6 H, gem. OMe); 3.77 (s, 3 H, NOME); 7.48, 8.60 (both m, 3 H and 2 H, Ph)	23.28 (gem. Me); 52.47 (gem. OMe); 63.74 (NOMe); 89.48 (CMe <sub>2</sub> ); 112.31 (C(OMe) <sub>2</sub> ); 133.51 (C=NO); Ph: 126.39 (C <sub>i</sub> ); 126.91 (C <sub>o</sub> ); 128.11 (C <sub>m</sub> ); 130.18 (C <sub>p</sub> )
31	(CD <sub>3</sub> ) <sub>2</sub> CO	1.40 (s, 6 H, gem. Me); 4.20, 4.34 (both m, each 2 H, CH <sub>2</sub> CH <sub>2</sub> ); 3.71 (s, 3 H, NOME); 7.45, 7.87 (both m, 3 H and 2 H, Ph)	25.84 (gem. Me); 66.38 (CH <sub>2</sub> CH <sub>2</sub> ); 64.65 (NOMe); 95.22 (CMe <sub>2</sub> ); 119.93 (O—C—O); 166.23 (C=N); Ph: 133.01 (C <sub>i</sub> ); 128.29 (C <sub>o</sub> ); 129.07 (C <sub>m</sub> ); 131.41 (C <sub>p</sub> )
32	(CD <sub>3</sub> ) <sub>2</sub> CO	1.48 (s, 6 H, gem. Me); 4.13 (m, 4 H, CH <sub>2</sub> CH <sub>2</sub> ); 3.72 (s, 3 H, NOME); 7.48, 7.86 (both m, 3 H and 2 H, Ph)	23.65 (gem. Me); 66.13 (CH <sub>2</sub> CH <sub>2</sub> ); 65.01 (NOMe); 69.22 (CMe <sub>2</sub> ); 128.87 (O—C—O); 178.27 (C=N); Ph: 133.06 (C <sub>i</sub> ); 128.97 (C <sub>o</sub> ); 129.35 (C <sub>m</sub> ); 131.91 (C <sub>p</sub> )

<sup>a</sup> Acyclic tautomer.<sup>b</sup> Cyclic tautomer.

4,4-Dimethoxy-1,2,2,5,5-pentamethyltetrahydroimidazole-3-oxyl (10) was synthesized\* by oxidation of 1,2,2,5,5-pentamethyl-2,5-dihydroimidazole 3-oxide with PbO<sub>2</sub> in methanol for 10 to 14 days. The syntheses of compounds 20, 27, 3a—c, 2a, and 7 were described previously.<sup>2,3</sup> Condensation of *N*-(2-hydroxy-1,1-dimethyl-2-phenylethyl)hydroxylamine with 4-methoxybenzaldehyde, performed according to the known procedure,<sup>3</sup> resulted in *N*-(2-hydroxy-1,1-dimethyl-2-phenylethyl)-α-(4-methoxyphenyl)nitron (34), whose oxidation in methanol (by analogy with the published data<sup>3</sup>) gave SNR 3d. Nitron 34, <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>SO), δ: 1.28, 1.50 (both s, each 3 H, gem. Me); 3.79 (s, 3 H, OMe); 5.15 (d, 1 H, OH, *J* = 5 Hz); 6.00 (d, 1 H, CH—OH, *J* = 5 Hz); 7.49 (s, 1 H, N=CH); 6.97, 8.36 (AA'BB', C<sub>6</sub>H<sub>4</sub>, *J* = 9 Hz); 7.21, 7.30 (both m, 3 H and 2 H, Ph).

4,5-Dihydrooxazole *N*-oxides (2b—d) were obtained by reducing SNRs 3b—d according to the known procedure.<sup>6</sup>

*N*-(2-Aroyloxy-1,1-dimethyl-2-phenylethyl)hydroxylamines (11b,d) were isolated from samples 2b,d kept in air at 25 °C for more than 10 to 15 days. By the end of the transformation, the samples crystallized completely. The resulting compounds 11b,d were recrystallized from an ethyl acetate—hexane (4 : 1) mixture. <sup>1</sup>H NMR (CDCl<sub>3</sub>), δ, 11b: 1.09, 1.17 (both s, each 3 H, gem. Me); 6.23 (s, 1 H, CH); 7.46 (m, 5 H, Ph); 7.30, 8.10 (both m, 3 H and 2 H, OCOPh); 10d: 1.06, 1.24 (both s, each 3 H, gem. Me); 3.90 (s, 3 H, OMe); 6.22 (s, 1 H, CH); 7.48 (m, 5 H, Ph); 7.15, 8.11 (AA'BB', C<sub>6</sub>H<sub>4</sub>, *J* = 9 Hz). MS 10d (EI, 70 eV), *m/z* (*I*<sub>rel</sub> (%)): 315 [M<sup>+</sup>] (3.5), 297 [M<sup>+</sup> — H<sub>2</sub>O] (40).

**Reduction of SNRs 4, 5, 6a,b, 9, 10, 25, and 27 (general procedure).** Zinc powder (grade PTs 12, 1 g, 15 mmol) and NH<sub>4</sub>Cl (0.5 g, 9 mmol) were added by portions with stirring to a cooled (0 °C) solution of an SNR (5 mmol) in 15 mL of methanol. The reaction mixture was stirred until the color of the radical disappeared (0.5 to 5 h), and then the precipitate that formed was filtered off and the solvent removed *in vacuo*. The residue was dissolved in CHCl<sub>3</sub>, the precipitate was filtered off, and the solution was concentrated again. The resulting compounds 19, 26, and 28 were recrystallized from an ethyl acetate—hexane (2 : 1) mixture, while compound 13b from an

acetone—dichloromethane (1 : 1) mixture. Compounds 1, 12, 13a, and 14 were isolated by chromatography on silica gel Kieselgel 60 (Merck) in CHCl<sub>3</sub> (in the case of compound 12, the sorbent was pre-deactivated with 20% water). Compound 14 was recrystallized from hexane. The IR spectrum of the compound 1 obtained corresponds to the previously published data.<sup>1</sup> Compounds 16, 17, and 21 were isolated by chromatography on silica gel (CHCl<sub>3</sub> as the eluent) from samples 12, 13a, and 19 all kept at 25 °C. Compound 16 was recrystallized from methanol, and compound 21 from hexane.

**3-Hydroxy-2,2-dimethoxy-4,4-dimethyl-5-phenyltetrahydrooxazole (18)** was obtained by reducing SNR 7 as described<sup>3</sup> for SNR 3a. The solution formed upon treatment of SNR 7 with NH<sub>2</sub>OH in ethanol was concentrated *in vacuo* at a bath temperature not higher than 20 °C. The residue was dissolved in CHCl<sub>3</sub>, the precipitate was filtered off, and the solution was reconcentrated *in vacuo*. Compound 18 was not additionally purified before recording its spectra. The content of the major component was at least 90% (<sup>1</sup>H NMR data). Column chromatography on silica gel (CHCl<sub>3</sub> as the eluent) gave *N*-(2-methoxycarbonyloxy-1,1-dimethyl-2-phenylethyl)-hydroxylamine (22), <sup>1</sup>H NMR (CD<sub>3</sub>OD), δ: 0.96, 1.10 (both s, each 3 H, gem. Me); 3.74 (s, 3 H, OMe); 5.87 (s, 1 H, CH); 7.37 (m, 5 H, Ph).

**1,3-Dioxolane-2-spiro-5'-(2',2'-dimethyl-4'-phenyl-2',5'-dihydroimidazole-1'-oxyl) (25)** was obtained by oxidation of methoxynitron 13a with MnO<sub>2</sub> as described<sup>2</sup> for the synthesis of SNR 27. The chloroform solution formed upon extraction from the reaction mixture was washed with water, dried with MgSO<sub>4</sub>, and concentrated, and the residue was recrystallized from hexane.

**Synthesis of 1-methoxy-2,5-dihydroimidazoles 29, 30, 31, and 32 (general procedure).** A 0.2 *M* solution of methylhydrazine in diethyl ether was added dropwise to a solution of SNR 8, 9, 25, or 27 (1 mmol) in 1 mL of CHCl<sub>3</sub> or diethyl ether. After decolorization, the reaction mixture was placed in a refrigerator for 12 h, the precipitate of 20, 19, 26, or 28 that formed was filtered off, and the solution was concentrated *in vacuo*. The residue was chromatographed using plates with a nonfixed layer (Kieselgel 60, Merck, CHCl<sub>3</sub> as the eluent). The final compounds 29, 30, 31, and 32 were recrystallized from hexane.

This work was financially supported by the Russian Foundation for Basic Research (Project No. 97-03-32864a).

\* Synthesized by M. A. Voinov according to the known procedure.<sup>1</sup>

## References

1. V. F. Starichenko, I. A. Grigor'ev, S. A. Dikanov, V. I. Gulín, and L. B. Volodarsky, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1987, 125 [*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1987, **36**, 110 (Engl. Transl.)].
2. I. A. Grigor'ev, I. A. Kirilyuk, and L. B. Volodarsky, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1989, 1624 [*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1989, **38**, 1488 (Engl. Transl.)].
3. S. M. Bakunova, I. A. Grigor'ev, I. A. Kirilyuk, Yu. V. Gatilov, I. Yu. Bagryanskaya, and L. B. Volodarsky, *Izv. Akad. Nauk, Ser. Khim.*, 1992, 966 [*Bull. Russ. Acad. Sci., Div. Chem. Sci.*, 1992, **41**, 758 (Engl. Transl.)].
4. I. A. Kirilyuk, I. A. Grigor'ev, and L. B. Volodarsky, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1991, 2113 [*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1991, **40**, 1871 (Engl. Transl.)].
5. I. A. Kirilyuk, I. A. Grigor'ev, and L. B. Volodarsky, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1991, 2122 [*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1991, **40**, 1880 (Engl. Transl.)].
6. G. I. Shchukin, I. A. Grigor'ev, L. A. Vishnivetskaya, and L. B. Volodarskii, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1988, 1944 [*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1988, **37**, 1743 (Engl. Transl.)].
7. J. A. Warshaw, D. E. Gallis, B. J. Asken, O. J. Gonzales, and D. R. Grist, *J. Org. Chem.*, 1989, **54**, 1736.
8. S. P. Ashburn and R. M. Coates, *J. Org. Chem.*, 1984, **49**, 3127.
9. G. I. Shchukin, I. A. Grigor'ev, and L. B. Volodarsky, *Khim. Geterotsikl. Soedin.*, 1990, 478 [*Chem. Heterocycl. Comp.*, 1990 (Engl. Transl.)].
10. D. E. Gallis, J. A. Warshaw, B. J. Asken, and D. R. Grist, *Collect. Czech. Chem. Commun.*, 1993, **58**, 125.
11. G. I. Shchukin, I. A. Grigor'ev, and L. B. Volodarsky, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1983, 2357 [*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1983, **32**, 2123 (Engl. Transl.)].
12. I. A. Grigor'ev, V. V. Martin, G. I. Shchukin, V. I. Mamatyuk, and L. B. Volodarsky, *Khim. Geterotsikl. Soedin.*, 1985, 247 [*Chem. Heterocycl. Comp.*, 1985 (Engl. Transl.)].
13. I. A. Grigor'ev, G. I. Shchukin, V. V. Martin, and V. I. Mamatyuk, *Khim. Geterotsikl. Soedin.*, 1985, 252 [*Chem. Heterocycl. Comp.*, 1985 (Engl. Transl.)].
14. I. A. Grigor'ev, V. I. Mamatyuk, G. I. Shchukin, V. V. Martin, and L. B. Volodarsky, *Khim. Geterotsikl. Soedin.*, 1986, 1065 [*Chem. Heterocycl. Comp.*, 1986 (Engl. Transl.)].
15. I. A. Grigor'ev, I. A. Kirilyuk, and L. B. Volodarsky, *Khim. Geterotsikl. Soedin.*, 1988, 1640 [*Chem. Heterocycl. Comp.*, 1988 (Engl. Transl.)].

Received January 12, 1999;  
in revised form April 23, 1999